PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - All-cause Mortality, Cardiovascular Hospitalization and NT-proBNP in Variant ATTR-CM from ATTRibute-CM

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Time from First Recorded Clinical Manifestation to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using U.S. Claims Data

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Cause of Death in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from ATTRibute-CM

PRESENTATION · Apr 2025 · PDF

BBIO - Canavan GTx BBP-812 - NTSAD 2025 - CANaspire Program Updates

PRESENTATION · Apr 2025 · PDF

BBIO - Acoramidis TTR - ACC 2025 - Early Increases in Serum Transthyretin Level Reduced Cardiovascular-related Hospitalizations and Mortality

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Addition of Another TTR Stabilizer Did Not Further Increase Serum TTR Levels

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Improvements in Serum TTR Levels in Variant Population

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Pre-specified NT-proBNP Sensitivity Analyses

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Improvements in NYHA Class at Month 30 Versus Placebo

PRESENTATION · Mar 2025 · PDF

BBIO - Acoramidis TTR - ACC 2025 - Pre-specified Sensitivity Analyses Addressed Use of Another TTR Stabilizer in ATTRibute-CM